Myeloma and Plasma Cell Disorders

Shaji Kumar MD and Sagar Lonial MD review data from key myeloma presentations at the 2016 American Society of Hematology Annual Meeting.

Share

Program Content

Activities

  • MRD With Daratumumab in R/R MM
    Daratumumab Combinations Increase MRD Negativity vs Rd or Vd Alone in Relapsed/Refractory Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 05, 2016

    Expires: December 04, 2017

  • Response-Based MM Induction
    Phase III Myeloma XI: Response-Adapted Induction Improves Outcomes in Newly Diagnosed Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 06, 2016

    Expires: December 05, 2017

  • Selinexor + Dex in Ref MM
    Phase II STORM Trial: Selinexor + Dexamethasone Is Active in Patients With Heavily Pretreated Refractory MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 06, 2016

    Expires: December 05, 2017

  • Car/Pom/Dex in RR MM
    Phase I/II Trial: Weekly Carfilzomib, Pomalidomide, and Dexamethasone in R/R Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 07, 2016

    Expires: December 06, 2017

  • Venetoclax in R/R Myeloma
    Venetoclax Monotherapy for Relapsed/Refractory MM: Phase I Results
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 07, 2016

    Expires: December 06, 2017

  • SC Daratumumab in MM (PAVO)
    Phase Ib PAVO Study: Subcutaneous Daratumumab in Relapsed/Refractory Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 07, 2016

    Expires: December 06, 2017

  • Pembro + Pom/Dex in R/R MM
    Phase II Study: Pembrolizumab Plus Pomalidomide and Dexamethasone Active in R/R Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 08, 2016

    Expires: December 07, 2017

  • IFM Phase II: KRd in MM
    IFM Phase II Study: KRd Induction and Consolidation Before Len Maintenance Highly Effective in Newly Diagnosed MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2016

    Expires: December 08, 2017

  • STaMINA: Post-ASCT Tx in MM
    Phase III STaMINA Trial: Similar PFS With Single ASCT, Single ASCT Followed by RVD Consolidation, and Tandem ASCT in Frontline MM Treatment
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2016

    Expires: December 08, 2017

  • Dara/Pom/Dex in RR MM
    Daratumumab/Pom/Dex Salvage Beneficial in R/R MM Single Institution Retrospective Analysis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2016

    Expires: December 11, 2017

  • Downloadable Slideset
    Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 27, 2016

    Expires: December 26, 2017

Provided by

ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen